I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2018
February 07, 2018
Share
I'rom Group Co., Ltd. reported consolidated earnings results for the nine months ended December 2017. Net sales were JPY 6,191 million compared to JPY 2,972 million a year ago. Operating income was JPY 769 million compared to loss of JPY 241 million a year ago. Ordinary income was JPY 819 million compared to loss of JPY 193 million a year ago. Net income attributable to owners of parent was JPY 1,457 million compared to loss of JPY 212 million a year ago. Diluted net income per share was JPY 125.14.
For the fiscal year ending March 2018, on consolidated basis, net sales to be JPY 9,500 million, operating income to be JPY 1,000 million, ordinary income to be JPY 1,100 million, net income attributable to owners of parent to be JPY 1,500 million and net income per share to be JPY 131.45.
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
I'rom Group Co., Ltd. Reports Consolidated Earnings Results for the Nine Months Ended December 2017; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 2018